Immediate Impact
18 standout
Citing Papers
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
2025 Standout
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
2025 Standout
Works of Leslie Gilham being referenced
Diversity, inclusion, and patient (pt)-centricity in the randomized, double-blind, phase III ASTEFANIA study of ado-trastuzumab emtansine (T-DM1) ± atezolizumab in pts with HER2-positive early breast cancer (EBC) with residual invasive disease after preoperative chemotherapy and anti-HER2 therapy.
2022
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer
2022
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Leslie Gilham | 83 | 9 | 39 | 42 | 39 | 15 | 145 | |
| Kate Law | 71 | 17 | 53 | 46 | 38 | 22 | 231 | |
| Feitong Lei | 68 | 6 | 16 | 23 | 19 | 19 | 195 | |
| Shauna McManus | 55 | 2 | 27 | 42 | 36 | 33 | 183 | |
| Chioma Asuzu | 96 | 4 | 39 | 59 | 47 | 21 | 196 | |
| Csaba László Dégi | 94 | 1 | 28 | 52 | 38 | 20 | 174 | |
| Giuliana Giuliani | 32 | 28 | 18 | 39 | 23 | 19 | 199 | |
| Omolara Fatiregun | 82 | 12 | 28 | 27 | 19 | 22 | 136 | |
| Brennan Parmelee Streck | 90 | 69 | 55 | 45 | 14 | 177 | ||
| Ruth Tarrant | 48 | 4 | 116 | 43 | 18 | 13 | 222 | |
| Francisco Iacobelli | 119 | 3 | 39 | 49 | 34 | 21 | 214 |
All Works
Loading papers...